A new UCL spin-out company – Autolus – is being launched today to develop and commercialise a new generation of engineered T-cell therapies for haematological and solid tumours, with the backing of £30m in investment from healthcare investment company Syncona.
UCL, Intel and Imperial poised to establish Institute for Sustainable Connected Cities
19 January 2012
UCL, Imperial College London and Intel have signed a Memorandum of
Understanding (MoU) with the aim of establishing an Institute for
Sustainable Connected Cities. Read more...